A phase II trial of extended induction epratuzumab and rituximab for previously untreated follicular lymphoma: CALGB 50701

Rituximab combined with chemotherapy has improved the survival of previously untreated patients with follicular lymphoma (FL). Nevertheless, many patients neither want nor can tolerate chemotherapy, leading to interest in biological approaches. Epratuzumab is a humanized anti-CD22 monoclonal antibod...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Autori principali: Grant, Barbara W., Jung, Sin-Ho, Johnson, Jeffrey L., Kostakoglu, Lale, His, Eric, Byrd, John C., Jones, Jeffrey, Leonard, John P., Martin, S. Eric, Cheson, Bruce D.
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2013
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC3828050/
https://ncbi.nlm.nih.gov/pubmed/23922187
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1002/cncr.28299
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi